The study links architectural changes to impaired B cell maturation and lymphoma predisposition, with Tet2, Kmt2d, and Dusp4 affected by loop loss.

Architectural tumor suppression is a new concept showing that disruption of 3D genome architecture, not just gene mutations, can predispose to lymphoma.

The researchers propose treatments that restore DNA looping or mimic its effects, shifting cancer therapy toward repairing genome architecture alongside correcting genetic mutations.

AI-driven analysis of Hi-C, single-cell RNA sequencing, and epigenetic data revealed how partial loss of architectural proteins reshapes the 3D genome and gene expression, guiding diagnostics and therapeutics.

Role of AI and data integration: AI analytics integrate Hi-C maps, single-cell RNA sequencing, and epigenetic data to show how architectural changes propagate to gene expression and cell fate.

Authoritative stance: Dr. Martin Rivas says architecture is as important as the genetic code in cancer development and treatment, signaling a paradigm shift.

A new study presented at ASH 2025 shows subtle disruptions in the 3D architecture of DNA predispose individuals to lymphoma, introducing architectural tumor suppression.

Biological consequence: The disrupted looping creates a bottleneck in B-cell maturation, preventing them from becoming plasma cells and increasing malignant transformation risk.

Analogy: DNA architecture is like a city’s roads and neighborhoods, where disappearing roads (loops) sever connections and enable cancer.

Therapeutic potential: Future therapies could restore proper enhancer–promoter loops or mimic their effects to reactivate tumor suppressor genes, guiding treatment toward genome-architecture repair.

Mechanism: Partial loss (haploinsufficiency) of architectural proteins SMC3 or CTCF disrupts short-range enhancer–promoter loops that keep tumor suppressor genes like Tet2, Kmt2d, and Dusp4 active, without breaking overall genome structure.

Clinical implication: DLBCL patients with lower SMC3 expression have worse prognosis, suggesting genome architecture as a prognostic biomarker and therapeutic target.